CC 90003

Drug Profile

CC 90003

Alternative Names: CC-90003; ERK inhibitor - Celgene

Latest Information Update: 09 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Celgene Corporation
  • Class Antineoplastics
  • Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 05 Jun 2017 Updated safety, efficacy and pharmacokinetic data from a phase Ia trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) presented results of the trial at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 22 Aug 2016 Celgene terminates a phase Ia trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (NCT02313012)
  • 05 Dec 2014 Celgene plans a phase Ia trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (NCT02313012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top